Genetics provides new individualized therapeutic targets for Parkinson’s disease

Eric Joshua Garcia, Ellen Sidransky

The identification of genes increasing one’s risk of developing common, complex disorders like Parkinson’s disease (PD) can provide novel therapeutic opportunities. A prime example of this are the consequences of mutations in GBA1, the gene responsible for the lysosomal storage disorder Gaucher disease (GD). GD is a multi-system disorder, primarily affecting tissues of the reticuloendothelial system. A subset of patients with GD also have neuronopathic manifestations (types 2 and 3 GD). In addition, there is an established association between GD and seemingly-unrelated movement disorders. First identified through clinical studies in patients and families with GD, mutations in GBA1 are the most significant genetic risk factor for PD and associated neurodegenerative disorders, including dementia with Lewy bodies and rapid eye movements sleep behavior disorders (Sidransky et al., 2009; Sidransky and Lopez, 2012; Honeycutt et al., 2019). This discovery has directed increased attention to lysosomal dysfunction in PD pathogenesis, rendering glucocerebrosidase (GCase), the enzyme encoded by GBA1, an attractive target for therapeutic development, as recently reviewed by Chen et al. (2020).

The mechanisms underlying the association between mutations in GBA1 and parkinsonism are still not fully understood. Different hypotheses have been reviewed extensively elsewhere (Blannidi et al., 2019; Do et al., 2019; Avenali et al., 2020). However, there appears to clearly be an inverse relationship between levels of glucocerebrosidase and the accumulation of alpha-synuclein. Furthermore, enzymatic studies of patients with PD reveal that even those without GBA1 mutations have reduced levels of glucocerebrosidase. Thus, therapies that increase glucocerebrosidase may have broad implications for the treatment of parkinsonism in general.

While 4–20% of patients with PD, depending on ethnicity, carry mutations in GBA1, the penetrance is very low. Interestingly, patients with PD carrying GBA1 mutations have an earlier age-of-onset and faster disease progression of parkinsonian manifestations. However, a majority of GBA1 mutation carriers, even those with close family members with PD, do not develop parkinsonism (Sidransky and Lopez, 2012). Thus, other genetic and/or non-genetic modifiers may impact whether GBA1 mutation carriers eventually go on to develop PD. Identifying these secondary risk factors, or “modifiers,” is particularly challenging, but these modifiers can have great significance and may potentially identify additional pathways or regulators that may serve as effective therapeutic targets (Davidson et al., 2018).

Enzyme replacement therapy, the first effective treatment for GD, reverses the hallmark symptoms of amnesia, thrombocytopenia, and hepatosplenomegaly. Initially derived from placenta, several approved forms of the recombinant enzyme are now available. Though enzyme replacement therapy ameliorates the visceral phenotypes observed in patients, it does not effectively treat the neurological dysfunction in neuronopathic forms of GD due to its failure to cross the blood-brain barrier. Similarly, substrate reduction therapy, which reduces the synthesis of the stored sphingolipids, is ineffective in reversing neuronopathic symptoms (Bennett and Mohan, 2013). Given that GBA1 mutation carriers are at an increased risk of developing PD, novel therapeutics are needed to effectively treat the parkinsonian manifestations in patients with GBA1-associated PD, and potentially, in other patients with PD.

To address this issue, multiple therapeutic options have focused on the delivery of GCase to the brain using several different methods. A study performed by Massaro et al. (2018) demonstrated that fetal intracranial injection of an adeno-associated virus serotype 9 (AAV9) vector with the Gba2 gene reconstituted neuronal GCase expression in a mouse model of neuronopathic GD. Long-term assessments of efficacy of intracerebroventricular and intravenous gene therapy showed that treated neuronopathic GD mice survived at least 180 days and were indistinguishable from age-matched controls. A similar study conducted by Rocha et al. (2015) demonstrated the effectiveness of intracerebral injection of AAV-GBA1 vector in a mouse model over-expressing A53T alpha-synuclein in reducing insoluble α-synuclein aggregates in the substantia nigra and striatum. AAV vectors provide an attractive mode of delivery due to their non-integrative nature and its selective delivery to the central nervous system.

Pharmacological small-molecule chaperones serve as another attractive approach to treating patients with GBA1-associated PD. Since they have the ability to cross the blood-brain barrier and directly bind to mutant GCase, these chaperones are prime candidates for ameliorating the neurodegeneration seen in GBA1-associated PD and potentially idiopathic PD. Inhibitory chaperones have been investigated as GCase chaperones. A recently identified inhibitory chaperone, Ambroxol has been shown to increase neuronal GCase activity in both mice and non-human primates. Several clinical trials of Ambroxol are underway aiming to evaluate its effectiveness in improving the molecular dysfunction resulting from GCase deficiency and the neuromotor impairment observed in PD. However, the search continues to identify new chaperones that also do not have an inhibitory component. As explored in the review by Chen et al. (2020), efforts were focused on screening for non-inhibitory chaperones by performing a high-throughput screen of 250,000 compounds using tissue samples derived from a GD patient as the source of mutant enzyme. This yielded two non-inhibitory compounds, NCGC607 and NCGC758, that were further studied in midbrain dopaminergic neurons generated from patient-derived iPSCs. Both compounds have demonstrated increases in enzyme levels and activity, reduction of GCase substrates and GCase activity lower alpha-synuclein levels and remove alpha-synuclein aggregates, respectively.

Although targeting the GCase enzyme is imperative for existing and future GD therapeutic development, strategies focusing on proteins that modify the disease progression can also be pursued to discover novel and efficacious therapeutics. GD, despite being a Mendelian disorder, is hallmarked by vast phenotypic heterogeneity. It is often difficult to use genotype-phenotype correlation to explain the various visceral and neuronopathic manifestations observed in patients. It seems certain that GD has other “modifiers” that modulate disease progression. Furthermore, the association of GD and PD further complicates the picture, for both homozygous and heterozygous GBA1 mutation carriers have increased PD risk. The identification of these modifiers in a rare disorder is particularly challenging. However, a few candidate modifiers of GD have been identified, including PSAP and SCARB2, as explored in a review by Davidson et al. (2018).

PSAP, or prosaposin, is cleaved to form its by-product, Saposin C (Sap C). As an activator of GCase activity, SapC has been shown to modulate some of the disease symptomology of GD. Mice deficient in both Gba and Psap exhibited a greater disease burden when compared to mice who were deficient in only one of the two proteins (Sun et al., 2010). Additionally, chemically synthesized Sap C increased GCase activity and stabilized GCase (Yoneshige et al., 2015). By combining Sap C and GCase treatments, current therapies might be improved to increase efficacy. A recent study by Oji et al. (2020) also suggests that variants in another by-product of PSAP, Saposin D (Sap D), are associated with PD. Pathogenic variants in the Sap D domain of PSAP were identified...
in patients with autosomal dominant PD and several intronic variants were described as a susceptibility region for sporadic PD. Despite the rarity of mutations in the Sap D domain of PSAP and the conclusion that the contribution of Sap D to PD pathology is independent of sphingolipid hydrolyase deficiencies, the results of the study implicating Sap D domain mutations in PD alpha-synuclein aggregation and loss of dopaminergic neurons point to the utility of identifying modifiers for developing targeted therapeutics.

SCAR82, encoding for the GCase transporter LiMP-2, has also been identified as a potential modifier of GD. Proper GCase trafficking is dependent on the pivotal interaction between LiMP-2 and GCase, with LiMP-2 deficient mice models exhibiting reduced GCase activity and expression. Mutations in SCAR82 results in different disorders with neurological manifestations, including neurodegeneration and alpha-synuclein accumulation, and has been implicated in myoclonic epilepsy. The accumulation of alpha-synuclein seen is of particular interest, suggesting that SCAR82 might be pursued to address parkinsonian symptoms in GBA1-associated PD.

In addition to these two GCase-related proteins, the use of newer genomic strategies may elucidate further disease modifiers that contribute to phenotypic heterogeneity in GD (Davidson et al., 2018). Linkage analysis, CRISPR/RNAi screens, and genome-wide association studies were all posited as helpful approaches to identify genetic modifiers. Furthermore, “epigenetic modifiers” could also contribute to discordant GD phenotypes (Hassan et al., 2017). In GD, with discordant sub-pairs and even discordant monozygotic twins, gene variants alone cannot fully explain the disparity of symptoms. The inclusion of both endogenous and endogenous stimuli impacting the dysregulation of the epigenetic mechanisms in GBA1 mutation carriers add another layer of intricacy complicating the search for non-GCase modifiers that may serve as therapeutic targets.

Through the development and availability of various “omics” technologies, distinguishing the most probable candidate modifiers is now becoming a feasible task. Whole-genome sequencing and whole-exome sequencing provide platforms to identify significant intronic and exonic variants that could contribute to the development of PD in family and large-cohort studies (Bandres-Ciga et al., 2020).

Microarrays and RNAseq data can contribute transcriptomic insights based on differentially expressed genes to distinguish biologically significant pathways that can aid in finding probable modifiers. To investigate epigenomic contributions to GD and even GBA1-associated PD progression, DNA methylation arrays, small RNA sequencing, and ChIP-seq could be employed. Using mass spectrometry, proteomics analyses could aid in identifying other protein modifiers like PSAP and SCAR82. Similarly, genetic and environmental contribution to metabolomics and their downstream effects in GBA1 mutation carriers could be determined by employing mass spectrometry and nuclear magnetic resonance spectroscopy. Recent advances in single cell technologies present a unique opportunity to identify modifiers in not only tissues, but in specific cellular populations as well. From scRNA-seq to scATAC-seq, numerous existing “omics” technologies can be expanded upon with greater resolution for more focused investigations of interactions with GCase and modifiers. However, it will be the careful and deliberate integration of all of these various “omics” platforms which will allow for powerful and effective analysis for the most plausible candidate modifiers for GD and GBA1-associated PD.

Targeting and replenishing GCase has proven to be effective in treating patients with GD. However, the inability for enzyme replacement therapy and substrate reduction therapy to reverse neuronopathic symptoms continues to be an obstacle in treating neuronopathic and GBA1-associated PD. The possibility of targeting proteins other than GCase may eventually provide alternative avenues to treating PD symptoms and neuronopathic manifestations. In the era of personalized medicine, it becomes even more imperative to approach treatment of patients with GD and those with PD using a holistic strategy (Bandres-Ciga et al., 2020). Though further research is needed before effective treatments and therapeutics can be established, identifying modifiers of GD and its association with PD may prove to be a practical starting point. Ultimately, these modifiers of GD and GBA1-associated PD could provide novel insights regarding disease progression and, most importantly, other targets for developing therapeutics.

Eric Joshua Garcia, Ellen Sidransky *Medical Genetic Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, USA.

*Correspondence to: Ellen Sidransky, MD, idranse@mail.nih.gov.

References

Avenali M, Blandini F, Cerr i S (2020) Glucocerebrosidase defects as a major risk factor for Parkinson’s disease. Front Aging Neurosci 12:97.

Bandres-Ciga S, Diez-Fairen M, Kim J, Singleton AB (2020) Genetics of Parkinson’s disease: An introspection of its journey towards precision medicine. Neurobiol Dis 143:104782.

Bennett LL, Mohan D (2013) Gaucher disease and its treatment options. Ann Pharmacother 47:1182-1193.

Blandini F, Cilia R, Cervi S, Pezzoli G, Schapira AHV, Mullin S, Lancejo II (2019) Glucocerebrosidase mutations and synucleinopathies: Toward a model of precision medicine. Mov Disord 34:9-21.

Chen Y, Sam R, Sharma P, Chen L, Do J, Sidransky E (2020) Glucocerebrosidase as a therapeutic target for Parkinson’s disease. Expert Opin Ther Targets 24:287-294.

Davidson BA, Hassan S, Garcia EL, Tayebi N, Sidransky E (2018) Exploring genetic modifiers of Gaucher disease: The next horizon. Hum Mutat 39:1739-1751.

Do J, McKinney C, Sharma P, Sidransky E (2019) Glucocerebrosidase and its relevance to Parkinson disease. Mol Neurodegener 14:36.

Hassan S, Sidransky E, Tayebi N (2017) The role of epigenetics in lysosomal storage disorders: Uncharted territory. Mol Genet Metab 122:10-18.

Honeycutt L, Montplaisir JY, Gagnon JY, Ruskey J, Pelletier A, Gan-Or Z, Postuma RB (2019) Glucocerebrosidase mutations and phenoclonization of REM sleep behavior disorder to parkinsonism and dementia. Parkinsonism Relat Disord 65:230-233.

Massaro G, Mattar CNZ, Wong AMS, Sirka E, Buckley SMK, Herbert BR, Karlsson S, Percheau DP, Burke D, Heales S, Richard-Londt A, Brandner S, Huebecker M, Priestman DA, Platt FM, Mills K, Biswas A, Cooper JD, Chan KY, Cheng SH, et al. (2018) Fetal gene therapy for neurodegen erative disease of infants. Nat Med 24:1317-1323.

Oji Y, Hatano T, Uemo S, Funayama M, Ishikawa KI, Okuzumi A, Noda S, Sato S, Satake W, Toda T, Li Y, Hino-Takai T, Kukita S, Tsunemi T, Yoshino H, Nishio K, Hattori T, Mizutani Y, Mutoh T, Yokochi K, et al. (2020) Variants in saposin D domain of prosaposin gene linked to Parkinson’s disease. Brain 143:1190-1205.

Rocha EM, Smith GA, Park E, Cao H, Brown E, Hayes MA, Beagan J, Mclean JR, Izen SC, Perez-Torres E, Hallett PJ, Isacson O (2015) Glucocerebrosidase gene therapy prevents α-synucleinopathy of midbrain dopamine neurons. Neurobiol Dis 82:949-503.

Sidransky E, Lopez G (2012) The link between the GBA gene and parkinsonism. Lancet Neurol 11:986-998.

Sidransky E, Nalls MA, Aslly JG, Aharon-Peretz J, Arnesi G, Barbosa ER, Bar-Shira A, Berg D, Brag J, Brice A, Chen CM, Clark LN, Condroyer C, De Marco EV, Dürr A, Edlan MJ, Fahn S, Farris MJ, Fung HC, Gan-Or Z, Gasser T, et al. (2009) Multicenter analysis of glucocerebrosidase mutations in Parkinson’s disease. N Engl J Med 361:1651-1661.

Sun Y, Liu B, Ran H, Skelton MR, Williams MT, Vorhees Cv, Kitatani K, Hannun YA, Witte DP, Xu YH, Grabowski GA (2010) Neuropathic Gaucher disease in the mouse: viable combined selective saposin C deficiency and mutant glucocerebrosidase (V394A) mice with glucosylsphingosine and glucosylceramide accumulation and progressive neurological deficits. Hum Mol Genet 19:1088-1097.

Yoneshige A, Muto M, Watanabe T, Hojo H, Matsuda J (2015) The effects of chemically synthesized saposins C on glucosylceramide β-glucosidase. Clin Biochem 48:1177-1180.